Skip to main navigation
  • Home
  • About Us
    • Our Commitment
    • The Story Behind Our Name
    • Leadership
    • Board of Directors
  • Our Approach
    • Precision Medicines
    • Overcoming Resistance
    • Novel Biomarkers
  • Pipeline
    • Ziftomenib
    • Tipifarnib
    • KO-2806
    • Scientific Publications
    • Access To Investigational Drugs Outside a Clinical Study
  • Patients & Caregivers
    • Acute Leukemias
    • Head & Neck Cancer
  • Clinical Trials
    • Overview of Clinical Trials
    • Ziftomenib Clinical Trials
    • KOMET-001 – AML
    • Tipifarnib Clinical Trials
    • AIM-HN – HNSCC
    • KURRENT-HN – HNSCC
    • KURRENT-LUNG
  • Careers
    • Values
    • Life At Kura
    • Benefits
    • Open Positions
  • Investors & Media
  • Contact
    Top Links
    • Investors & Media
    • Contact
    Main Menu
    • Home
    • About Us
      • Our Commitment
      • The Story Behind Our Name
      • Leadership
      • Board of Directors
    • Our Approach
      • Precision Medicines
      • Overcoming Resistance
      • Novel Biomarkers
    • Pipeline
      • Ziftomenib
      • Tipifarnib
      • KO-2806
      • Scientific Publications
      • Access To Investigational Drugs Outside a Clinical Study
    • Patients & Caregivers
      • Acute Leukemias
      • Head & Neck Cancer
    • Clinical Trials
      • Overview of Clinical Trials
      • Ziftomenib Clinical Trials
      • KOMET-001 – AML
      • Tipifarnib Clinical Trials
      • AIM-HN – HNSCC
      • KURRENT-HN – HNSCC
      • KURRENT-LUNG
    • Careers
      • Values
      • Life At Kura
      • Benefits
      • Open Positions
    • Investors & Media
    • Contact
    • MenuMenu

    SEC Filings

    Submenu
    IR Menu
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
      • SEC Filings
      • Annual Report and Proxy
      • Stock Quote
    • Analyst Coverage
    • FAQs
    • Contact

    Tools

    • Print
    • RSS Feeds
    • Email Alerts

    SEC Filing Keyword Search

    Filing date Form Description Filing Group View
    02-03-2023 SC 13G/A

    An amendment to the SC 13G filing

    Other
    0000093751-23-000145.pdf
    0000093751-23-000145.rtf
    View HTML
    01-31-2023 SC 13G/A

    An amendment to the SC 13G filing

    Other
    0001306550-23-005107.pdf
    0001306550-23-005107.rtf
    View HTML
    01-31-2023 4

    Statement of changes in beneficial ownership of securities

    3,4,5
    0001209191-23-005744.pdf
    0001209191-23-005744.rtf
    0001209191-23-005744.xls
    View HTML
    01-31-2023 4

    Statement of changes in beneficial ownership of securities

    3,4,5
    0001209191-23-005746.pdf
    0001209191-23-005746.rtf
    0001209191-23-005746.xls
    View HTML
    01-31-2023 4

    Statement of changes in beneficial ownership of securities

    3,4,5
    0001209191-23-005748.pdf
    0001209191-23-005748.rtf
    0001209191-23-005748.xls
    View HTML
    01-31-2023 4

    Statement of changes in beneficial ownership of securities

    3,4,5
    0001209191-23-005753.pdf
    0001209191-23-005753.rtf
    0001209191-23-005753.xls
    View HTML
    01-13-2023 8-K

    Report of unscheduled material events or corporate event

    Current Reports
    0001193125-23-008358.pdf
    0001193125-23-008358.rtf
    0001193125-23-008358.xls
    EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
    01-09-2023 8-K

    Report of unscheduled material events or corporate event

    Current Reports
    0001193125-23-004159.pdf
    0001193125-23-004159.rtf
    0001193125-23-004159.xls
    EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
    12-12-2022 8-K

    Report of unscheduled material events or corporate event

    Current Reports
    0001193125-22-302283.pdf
    0001193125-22-302283.rtf
    0001193125-22-302283.xls
    EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
    12-05-2022 SC 13G

    A statement of beneficial ownership of common stock by certain persons

    Other
    0000921895-22-003161.pdf
    0000921895-22-003161.rtf
    0000921895-22-003161.xls
    View HTML

    Pagination

    • Current page 1
    • Page 2
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9
    • Next page Next ›
    • Last page Last »

    Data provided by Kaleidoscope.

    Tools

    • Print
    • RSS Feeds
    • Email Alerts
    Footer Links - Top
    • About Us
    • Our Commitment
    • The Story Behind Our Name
    • Leadership
    • Board of Directors
    • Our Approach
    • Precision Medicines
    • Overcoming Resistance
    • Novel Biomarkers
    • Pipeline
    • Ziftomenib
    • Tipifarnib
    • KO-2806
    • Scientific Publications
    • Access to Investigational Drugs Outside a Clinical Study
    • Patients & Caregivers
    • Acute Leukemias
    • Head & Neck Cancer
    Footer Links - Clinical Trials
    • Clinical Trials
    • Overview of Clinical Trials
    • Ziftomenib Clinical Trials
    • KOMET-001 – AML
    • Tipifarnib Clinical Trials
    • AIM-HN – HNSCC
    • KURRENT-HN – HNSCC
    • KURRENT-LUNG
    Footer Links - Investors
    • Investors & Media
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • FAQs
    • Contact
    Footer Links - Careers
    • Careers
    • Values
    • Life at Kura
    • Benefits
    • Open Positions
    01 Footer Links - Contact
    • Contact

    Kura Oncology, Inc.
    12730 High Bluff Drive, Suite 400
    San Diego, CA 92130
    (858) 500-8800

    Kura Oncology, Inc.
    2 Seaport Lane, Suite 8A
    Boston, MA 02210
    (617) 588-3755

    Kura Oncology, Inc.
    5510 Morehouse Drive, Suite 110
    San Diego, California 92121

    © 2023 Kura Oncology, Inc. All Rights Reserved | Terms of Use| Privacy Policy

    Scroll to top